Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

New sulfonated distamycin A derivatives with bFGF complexing activity

M Ciomei1, W Pastori, M Mariani

  • 1Farmitalia Carlo Erba, Research Center, Experimental Oncology Laboratory, Milano, Italy.

Biochemical Pharmacology
|January 20, 1994
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Search for the Exclusive W Boson Hadronic Decays W^{±}→π^{±}γ, W^{±}→K^{±}γ and W^{±}→ρ^{±}γ with the ATLAS Detector.

Physical review letters·2024
Same author

Determination of the Relative Sign of the Higgs Boson Couplings to W and Z Bosons Using WH Production via Vector-Boson Fusion with the ATLAS Detector.

Physical review letters·2024
Same author

Statistical Combination of ATLAS Run 2 Searches for Charginos and Neutralinos at the LHC.

Physical review letters·2024
Same author

Combination of Measurements of the Top Quark Mass from Data Collected by the ATLAS and CMS Experiments at sqrt[s]=7 and 8 TeV.

Physical review letters·2024
Same author

Azimuthal Angle Correlations of Muons Produced via Heavy-Flavor Decays in 5.02 TeV Pb+Pb and pp Collisions with the ATLAS Detector.

Physical review letters·2024
Same author

Study of High-Transverse-Momentum Higgs Boson Production in Association with a Vector Boson in the qqbb Final State with the ATLAS Detector.

Physical review letters·2024

Novel sulfonated distamycin A derivatives were synthesized to block tumor angiogenesis by complexing growth factors. Two compounds, FCE 26644 and FCE 27164, showed significant antitumor potential by inhibiting key angiogenic factors.

Area of Science:

  • Oncology
  • Pharmacology
  • Biochemistry

Background:

  • Tumor growth relies on neoangiogenesis, making angiogenesis inhibitors potential antitumor agents.
  • Suramin, a polysulfonated naphthylurea, is hypothesized to block angiogenesis-promoting factors.
  • Developing novel compounds targeting angiogenesis is crucial for cancer therapy.

Purpose of the Study:

  • To synthesize novel sulfonated distamycin A derivatives.
  • To identify compounds that complex basic fibroblastic growth factor (bFGF) and other pro-angiogenic factors.
  • To evaluate these compounds' anti-angiogenic and antitumor potential.

Main Methods:

  • Synthesis and characterization of sulfonated distamycin A derivatives.
  • Inhibition assays for bFGF binding, in vivo bFGF-induced angiogenesis, and chorioallantoic membrane neovascularization.

Related Experiment Videos

  • Evaluation of inhibition of platelet-derived growth factor beta (PDGF beta) and interleukin-1 beta binding.
  • Mode of action studies using sequential binding assays and bFGF-induced tyrosine phosphorylation assays.

    • Main Results:

    • Two potent compounds, FCE 26644 and FCE 27164, were identified.
    • These compounds inhibited bFGF, PDGF beta, and interleukin-1 beta binding.
    • Activity was observed when compounds complexed growth factors, not when pre-administered with receptors.

    Conclusions:

    • FCE 26644 and FCE 27164 are promising novel anti-angiogenic agents.
    • Their mechanism involves complexing with growth factors, disrupting angiogenesis.
    • These compounds warrant further investigation for antitumor applications.